Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Ovaries01:26

Ovaries

The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of cuboidal...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncology Clinicians' Attitudes on Hormonal Therapy After Chemoradiotherapy for Cervical Cancer.

JAMA network open·2026
Same author

A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer.

Cancers·2026
Same author

Assessing the Value of Sequential Next-Generation Sequencing and Multiple Molecular Tumor Board Reviews for Patients With Solid-Tumor Malignancies.

JCO precision oncology·2026
Same author

M1 Macrophage-Engineered Vesicles Have Anti-Cancer Activity in Ovarian Cancer.

Cancer nanotechnology·2026
Same author

Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor.

Gynecologic oncology reports·2024
Same author

Malignant <i>STK11</i> adnexal tumor harboring a somatic mutation in a woman previously diagnosed with mesothelioma, a case report.

Gynecologic oncology reports·2024

Related Experiment Video

Updated: Jul 6, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Ovarian cancer.

Nishan Chobanian1, Charles S Dietrich

  • 1Gynecologic Oncology, Saint John's Mercy Medical Center, 607 S. New Ballas Road, Saint Louis, MO 63101, USA. chobnh@stlo.mercy.net

The Surgical Clinics of North America
|April 3, 2008
PubMed
Summary

Ovarian cancer is a leading cause of cancer death in women. Despite initial treatment success, most patients succumb to disease progression, highlighting a critical need for improved ovarian cancer therapies.

Area of Science:

  • Gynecologic Oncology
  • Cancer Epidemiology
  • Clinical Oncology

Background:

  • Ovarian cancer is the deadliest gynecologic malignancy, ranking fifth in female cancer deaths.
  • In 2007, an estimated 22,430 US women were diagnosed, with 15,280 deaths attributed to the disease.
  • Despite high initial response rates to surgery and chemotherapy (up to 80%), over 75% of patients experience disease progression and mortality.

Purpose of the Study:

  • To summarize the current epidemiological burden and clinical challenges of ovarian cancer.
  • To underscore the unmet need for more effective treatments for advanced ovarian cancer.
  • To provide context for ongoing research into novel ovarian cancer therapeutic strategies.

Main Methods:

  • This abstract is based on epidemiological data and clinical outcomes reported in the literature.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Related Experiment Videos

Last Updated: Jul 6, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

  • It synthesizes information on incidence, mortality, and treatment response rates for ovarian cancer.
  • No new experimental data were generated for this summary.

    • Main Results:

    • Ovarian cancer presents a significant public health challenge due to its high mortality rate.
    • The majority of ovarian cancer patients do not achieve long-term survival, even with standard treatments.
    • Disease progression remains the primary cause of death in ovarian cancer patients.

    Conclusions:

    • Ovarian cancer's high mortality rate, despite initial treatment efficacy, necessitates urgent advancements in therapeutic approaches.
    • The persistent challenge of disease progression underscores the need for novel strategies to improve long-term outcomes for ovarian cancer patients.
    • Further research is critical to overcome treatment resistance and reduce the devastating impact of ovarian cancer.